Home > Journals > European Journal of Physical and Rehabilitation Medicine > Past Issues > European Journal of Physical and Rehabilitation Medicine 2020 August;56(4) > European Journal of Physical and Rehabilitation Medicine 2020 August;56(4):469-78

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

SYSTEMATIC REVIEW   Freefree

European Journal of Physical and Rehabilitation Medicine 2020 August;56(4):469-78

DOI: 10.23736/S1973-9087.20.05820-7

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Improving characterization and diagnosis quality of myofascial pain syndrome: a systematic review of the clinical and biomarker overlap with delayed onset muscle soreness

Brian VADASZ 1, 3, Jacob GOHARI 1, Daniel W. WEST 2, 3, Liza GROSMAN-RIMON 3, Evan WRIGHT 4, Levent OZCAKAR 5, John SRBELY 6, Dinesh KUMBHARE 3

1 Technion American Medical School, The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel; 2 Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada; 3 Division of Physical Medicine and Rehabilitation, Toronto Rehabilitation Institute, University of Toronto, Toronto, ON, Canada; 4 Department of Pediatrics, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA; 5 Department of Physical and Rehabilitation Medicine, School of Medicine, Hacettepe University, Ankara, Turkey; 6 Department of Human Health and Nutritional Science, University of Guelph, Guelph, Canada



INTRODUCTION: Myofascial pain syndrome (MPS) is one of the most common conditions of chronic musculoskeletal pain, yet its mechanisms are still poorly understood. Delayed Onset Muscle Soreness (DOMS) is also a regional pain syndrome that has clinical similarities to MPS, but has been better investigated. Emerging research suggests that DOMS may be a valid experimental model for studying MPS; however, a comparison of the similarities and differences of these two conditions has previously not been performed. Herein, we aimed to identify the similarities and differences in the clinical features and biomarkers between DOMS and MPS in order to better define MPS and identify future areas of (DOMS-informed) MPS research.
EVIDENCE ACQUISITION: In order to identify similarities and differences in the clinical manifestation and biomarkers of DOMS and MPS, scoping literature searches were performed using Medline (1965-2019), Embase (1966-2019) and Central (1966-2019) databases. Fifty-three full-text articles were reviewed out of the 2836 articles retrieved in the search.
EVIDENCE SYNTHESIS: A scoping review of the literature demonstrated that DOMS and MPS similarly present as conditions of musculoskeletal pain that are associated with decreased strength and limited range of motion. However, while taut bands and discrete tender spots were described in DOMS, none of the studies reviewed have characterized whether these tender points represent the classic myofascial trigger point phenomenon observed in MPS. Certain systemic circulation biomarkers, including inflammatory cytokines and growth factors, were commonly elevated in MPS and DOMS; further research is needed to determine if other biomarkers that are currently characterized in DOMS are useful to enhance the clinical evaluation of MPS.
CONCLUSIONS: DOMS and MPS share clinical and biomarker similarities suggesting that DOMS may be a useful model for studying MPS.


KEY WORDS: Myofascial pain syndromes; Myalgia, Biomarkers; Trigger point

top of page